VIR – Vir Biotechnology, Inc.
Vir Biotechnology, Inc.VIR
$13.21Name : Vir Biotechnology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,262,486,784.00
EPSttm : -1.18
Vir Biotechnology, Inc.
$13.21
0.46%$0.06
VIR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
11.97
Margin Of Safety %
Put/Call OI Ratio
0.1
EPS Next Q Diff
0.07
EPS Last/This Y
1.87
EPS This/Next Y
-1.06
Price
13.16
Target Price
23.38
Analyst Recom
1.11
Performance Q
46.76
Upside
-224.6%
Beta
1.71
Ticker: VIR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | VIR | 11.31 | 0.10 | 0.04 | 13753 |
| 2026-10-13 | VIR | 10.62 | 0.10 | 0.01 | 13662 |
| 2026-10-14 | VIR | 10.43 | 0.10 | 0.00 | 13668 |
| 2026-10-15 | VIR | 10.46 | 0.10 | 0.02 | 13675 |
| 2026-10-16 | VIR | 9.97 | 0.10 | 0.03 | 13724 |
| 2026-10-19 | VIR | 10.21 | 0.10 | 0.03 | 10138 |
| 2026-10-20 | VIR | 10.74 | 0.09 | 0.08 | 10211 |
| 2026-10-21 | VIR | 10.56 | 0.09 | 0.25 | 10585 |
| 2026-10-22 | VIR | 10.42 | 0.10 | 0.31 | 10626 |
| 2026-10-23 | VIR | 10.56 | 0.10 | 0.28 | 10652 |
| 2026-10-26 | VIR | 11.05 | 0.10 | 0.02 | 10755 |
| 2026-10-27 | VIR | 11.57 | 0.10 | 0.00 | 10889 |
| 2026-10-28 | VIR | 11.94 | 0.10 | 0.00 | 11089 |
| 2026-10-29 | VIR | 11.74 | 0.09 | 0.01 | 11197 |
| 2026-10-30 | VIR | 11.31 | 0.09 | 0.00 | 11205 |
| 2026-11-02 | VIR | 11 | 0.10 | 2.63 | 11034 |
| 2026-11-03 | VIR | 11.23 | 0.10 | 0.40 | 11063 |
| 2026-11-04 | VIR | 11.77 | 0.10 | 0.02 | 11121 |
| 2026-11-05 | VIR | 11.06 | 0.10 | 0.00 | 11258 |
| 2026-11-06 | VIR | 12.21 | 0.10 | 0.04 | 11327 |
| 2026-11-09 | VIR | 13.65 | 0.10 | 0.06 | 12517 |
| 2026-11-10 | VIR | 13.16 | 0.10 | 0.01 | 12834 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | VIR | 11.30 | 37.5 | - | -1.76 |
| 2026-10-13 | VIR | 10.62 | 37.5 | - | -1.76 |
| 2026-10-14 | VIR | 10.43 | 37.5 | - | -1.76 |
| 2026-10-15 | VIR | 10.48 | 37.5 | - | -1.76 |
| 2026-10-16 | VIR | 9.97 | 37.5 | - | -1.76 |
| 2026-10-19 | VIR | 10.22 | 37.5 | - | -1.76 |
| 2026-10-20 | VIR | 10.22 | 37.5 | - | -1.76 |
| 2026-10-21 | VIR | 10.74 | 37.5 | - | -1.76 |
| 2026-10-22 | VIR | 10.42 | 37.5 | - | -1.76 |
| 2026-10-23 | VIR | 10.56 | 37.5 | - | -1.76 |
| 2026-10-26 | VIR | 11.05 | 37.5 | - | -1.76 |
| 2026-10-27 | VIR | 11.56 | 37.5 | - | -1.76 |
| 2026-10-28 | VIR | 11.94 | 37.5 | - | -1.76 |
| 2026-10-29 | VIR | 11.74 | 37.5 | - | -1.76 |
| 2026-10-30 | VIR | 11.30 | 37.5 | - | -1.76 |
| 2026-11-02 | VIR | 11.00 | 37.5 | - | -1.76 |
| 2026-11-04 | VIR | 11.77 | 36.3 | - | -1.77 |
| 2026-11-05 | VIR | 11.00 | 36.3 | - | -1.77 |
| 2026-11-06 | VIR | 12.20 | 36.3 | - | -1.77 |
| 2026-11-09 | VIR | 13.64 | -100.0 | - | -1.77 |
| 2026-11-10 | VIR | 13.16 | -5.7 | - | -1.29 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | VIR | -0.07 | 5.09 | 11.17 |
| 2026-10-13 | VIR | -0.07 | 5.09 | 11.17 |
| 2026-10-14 | VIR | -0.07 | 5.09 | 11.17 |
| 2026-10-15 | VIR | -0.07 | 5.09 | 11.17 |
| 2026-10-16 | VIR | -0.07 | 5.09 | 11.17 |
| 2026-10-19 | VIR | -0.07 | 5.07 | 11.17 |
| 2026-10-20 | VIR | -0.07 | 5.07 | 11.17 |
| 2026-10-21 | VIR | -0.07 | 5.07 | 11.17 |
| 2026-10-22 | VIR | -0.07 | 5.07 | 11.17 |
| 2026-10-23 | VIR | -0.07 | 5.07 | 11.17 |
| 2026-10-26 | VIR | -0.07 | 4.87 | 11.17 |
| 2026-10-27 | VIR | -0.07 | 4.87 | 12.11 |
| 2026-10-28 | VIR | -0.07 | 4.87 | 12.11 |
| 2026-10-29 | VIR | -0.07 | 4.87 | 12.11 |
| 2026-10-30 | VIR | -0.07 | 4.87 | 12.11 |
| 2026-11-02 | VIR | -0.07 | 3.23 | 12.11 |
| 2026-11-03 | VIR | -0.07 | 3.23 | 12.11 |
| 2026-11-05 | VIR | -0.02 | 3.23 | 12.11 |
| 2026-11-06 | VIR | -0.02 | 3.23 | 12.11 |
| 2026-11-09 | VIR | -0.02 | 3.97 | 11.97 |
| 2026-11-10 | VIR | -0.02 | 3.97 | 11.97 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.57
Avg. EPS Est. Current Quarter
-0.33
Avg. EPS Est. Next Quarter
-0.5
Insider Transactions
-0.02
Institutional Transactions
3.97
Beta
1.71
Average Sales Estimate Current Quarter
6
Average Sales Estimate Next Quarter
25
Fair Value
Quality Score
41
Growth Score
32
Sentiment Score
92
Actual DrawDown %
77.3
Max Drawdown 5-Year %
-92.1
Target Price
23.38
P/E
Forward P/E
PEG
P/S
7.44
P/B
2.49
P/Free Cash Flow
EPS
-1.26
Average EPS Est. Cur. Y
-1.29
EPS Next Y. (Est.)
-2.35
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-61.03
Relative Volume
0.64
Return on Equity vs Sector %
-46.9
Return on Equity vs Industry %
-27.2
EPS 1 7Days Diff
0.5
EPS 1 30Days Diff
0.46
EBIT Estimation
◆
VIR
Healthcare
$13.15
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
63.3
Range 1M
72.5%
Sup Dist
1.4%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
66.9%
EPS NY
-125.5%
52W%
86.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+77.8% upside
Upside
+77.8%
Quality
41
VIR — P/E HistoricalBiotechnology
Vir Biotechnology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 367
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR
Latest News
—
Caricamento notizie per VIR…
stock quote shares VIR – Vir Biotechnology, Inc. Stock Price stock today
news today VIR – Vir Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VIR – Vir Biotechnology, Inc. yahoo finance google finance
stock history VIR – Vir Biotechnology, Inc. invest stock market
stock prices VIR premarket after hours
ticker VIR fair value insiders trading